How many clinical trials are tracked for thyroid eye disease?

5 trials are tracked, 2 with published results.

thyroid eye disease Research

Thyroid eye disease: what the trials found

Teprotumumab (also referred to as TEPEZZA) has demonstrated significant efficacy in treating thyroid eye disease. Clinical trials showed a statistically significant reduction in proptosis at week 24, with mean changes of -2.41 mm and -0.92 mm respectively (p=0.0004) ².

In Phase 3 studies using Teprotumumab, high responder rates were observed for both proptosis reduction (82.9% vs 9.5%, p<0.001) and overall clinical response (78.0% vs 7.1%, p<0.001) ³. Furthermore, approximately 89.2% of patients achieved a ≥ 2 mm reduction in proptosis in the study eye without deterioration in the fellow eye at week 24 ⁴.

Teprotumumab also showed significant improvements in clinical activity scores (CAS). Specifically, 58.5% of patients were categorized as CAS responders compared to 21.4% in the control group (p<0.001) ³, and 65.6% achieved an EUGOGO amended CAS score of 0 or 1 at week 24 ⁴. Additionally, 75.0% of patients were identified as diplopia responders ⁴.

For the clinician treating this condition

Teprotumumab is associated with significant reductions in proptosis and improved clinical activity scores (CAS) in patients with thyroid eye disease.
High percentages of patients treated with Teprotumumab achieved a ≥ 2 mm reduction in proptosis without worsening in the fellow eye, while also showing high rates of diplopia response.

AI synthesis of 4 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.